drugset / Trial / NCT07537868

Effect of Montelukast on Inflammatory Markers and Cardiac Injury in Patients With Acute Myocardial Infarction

NCT07537868

Phase 2 Recruiting 80 enrolled October 6 University Mansoura University · collab
RandomizedParallel-groupTriple-blindOther

Summary

This is a randomized controlled clinical trial designed to evaluate the therapeutic effects of Montelukast in patients diagnosed with Acute Myocardial Infarction (AMI). The study aims to investigate whether the administration of Montelukast influences inflammatory markers and the extent of cardiac injury following a heart attack.Participants will be randomly assigned to receive either the active medication or a placebo to provide high-quality evidence regarding the drug's potential cardioprotective and anti-inflammatory properties. The trial is conducted through the Faculty of Pharmacy and Faculty of Medicine at Mansoura University

Timeline

Start
2026-04-20
Primary completion
2027-05
Completion
2027-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Montelukast Other / unclassified 10 mg Oral